New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Antoni Chan MD (Prof) synovialjoints
2 months ago
Abstr LB0009
Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up.
VTE: HR 1.61 (95% CI 0.97–2.66)
non-inferiority not demonstrated
MACE: HR 1.06 no cardiovascular excess
Serious infections: HR 1.32 (p<0.05)
@RheumNow https://t.co/NSNRJi9B4r
Antoni Chan MD (Prof) synovialjoints
2 months ago
Abstr LB0009
Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years.
Safety endpoints
VTE HR 1.61 non inferiority not met
Serious infections HR 1.32 (p<0.05)
MACE HR 1.06 reassuring
@RheumNow #EULAR2026 https://t.co/nR6TMowlYS
Mrinalini Dey DrMiniDey
2 months ago
#EULAR2026 Updated recommendations on the management of PMR &LVV.
A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles.
Watch this space for full guideline coming soon!
#EULAR2026
@RheumNow https://t.co/CUvaQVSU8k
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v
Janet Pope Janetbirdope
2 months ago
5 top abstracts in #Myositis @eular_org
1 #Nailfold #capillaries as an early marker of #IIM Rx
2 #brepocitinib +RCT #DM
3 & rapid skin improvement #CLASI
4 #Ab may help #IBM but neg primary endpoint
5 #criteria for #antisynthetase
#EULAR2026 @RheumNow
OP0168, 0166, 0164 POS264
Janet Pope Janetbirdope
2 months ago
Top 5 abst in #SjD
#anifrolumab +RCT
#ianalumab LTE Rx sustained
#telitatacept +LTE
#iana improves u/s parotids
#TYK2 sig in#SjD
OP0002, 0126, 127, 160 POS0284
#EULARbest #EULAR2026
@RheumNow @eular_org
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 LB0007 Phase 2 RCT of Nipocalimab, an FcRn-i in moderate-to-severe #SLE, with mandatory GC taper =<7.5mg/d by WK16: met primary endpoint at WK24 (SRI-4) vs PBO. Effect size better in Ab+, Ab-High & IFN-High. 23% had IgG<3 at WK58 but SIE. Phase 3 is underway @RheumNow https://t.co/EpgNOHcEqC
Janet Pope Janetbirdope
2 months ago
Do you target #DORIS / remission in #SLE pts
#EULAR2026 @RheumNow @eular_org
Janet Pope Janetbirdope
2 months ago
Aiming for #DORIS #SLE #remission
Or #LLDAS in #SLE
Related to ⬆️survival
#deep outcome in RCTs
➡️archived in #deucravacitinib ph2 #LTE
&
ph3 #dapirolizumab & #obintuzimab
-achieved in #CAR-T trials in #lupus
POS0683, 1364, 0695, OP0338
& several 🚗 T abst
#EULAR2026 @RheumNow
Nelly ZIADE 🍀 Nellziade
2 months ago
Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs?
RISE registry
Retrospective
N=60,206
Tirzepatide: lost 8%
Semaglutide: list 6%
At 12 months
PsA had the highest usage
OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr
Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs. EULAR is focused on systemic sclerosis as the rheumatic disease with the highest morbidity and mortality. New data presented at the EULAR 2026 Congress underscore key complications, and offer hope for a possible new therapeutic strategy.
CD19-directed CAR T-cell therapy has rapidly moved into autoimmune disease, driven in large part by striking reports in SLE, where sustained drug-free remission has raised the possibility of a true immune reset. In RA, where multiple effective therapeutic classes already exist, the relevance of such deep immune interventions remains uncertain.
Jiha Lee JihaRheum
2 months ago
BARI vs TNFi in VTE-enriched #RA pts (RA-BRIDGE + RA-BRANCH, n=3,640, ~3.7 yrs follow-up): VTE non-inferiority not met (HR 1.61, CI 0.97–2.66).
But absolute rates low (2.5% vs 1.7%) and MACE was similar (HR 1.06). Serious infections ↑ with BARI. @RheumNow #EULAR2026 LB0009
Aurelie Najm AurelieRheumo
2 months ago
What drives progression to difficult-to-treat RA?
20-year cohort 675pts
-18.8% developed D2T RA
-Younger age, higher HAQ & prior steroid exposure asso w/ D2T RA
-Earlier b/tsDMARD initiation protective
-No diff TNFi vs non-TNFi first-line strategy
Disease severity and https://t.co/SJDv9HCbLv
sheila RHEUMarampa
2 months ago
JAK-SPARE: Ph3 RCT on baricitinib for rem induxn in early PMR.
BARI was effective vs. PBO in inducing & maintaining GC free rem.
No new safety signals.
New tx option for PMR (esp early). Decreases GC dependence & side effects.
LB0005 @RheumNow #EULAR2026 https://t.co/mWrr1RdPCm
